Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species

被引:18
|
作者
Yang, Wu [1 ]
Wang, Yufeng [1 ]
Lai, Amy [1 ]
Clark, Charles G. [1 ]
Corte, James R. [1 ]
Fang, Tianan [1 ]
Gilligan, Paul J. [1 ]
Jeon, Yoon [1 ]
Pabbisetty, Kumar B. [1 ]
Rampulla, Richard A. [1 ]
Mathur, Arvind [1 ]
Kaspady, Mahammed [2 ]
Neithnadka, Premsai Rai [2 ]
Arumugam, Arunachalam [2 ]
Raju, Sivashankaran [2 ]
Rossi, Karen A. [1 ]
Myers, Joseph E., Jr. [1 ]
Sheriff, Steven [1 ]
Lou, Zhen [1 ]
Zheng, Joanna J. [1 ]
Chacko, Silvi A. [1 ]
Bozarth, Jeffrey M. [1 ]
Wu, Yiming [1 ]
Crain, Earl J. [1 ]
Wong, Pancras C. [1 ]
Seiffert, Dietmar A. [1 ]
Luettgen, Joseph M. [1 ]
Lam, Patrick Y. S. [1 ]
Wexler, Ruth R. [1 ]
Ewing, William R. [1 ]
机构
[1] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ 08540 USA
[2] Syngene Int Ltd, Biocon Bristol Myers Squibb R&D Ctr, Bangalore 560100, Karnataka, India
关键词
TERT-BUTANESULFINYL IMINES; FACTOR XA INHIBITORS; FACTOR-XI; THROMBUS PROPAGATION; PREVENTION; PYRIDINE;
D O I
10.1021/acs.jmedchem.0c00464
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Oral factor XIa (FXIa) inhibitors may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profile over existing antithrombotic agents. Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle. This resulted in identification of compound 4 with desired FXIa inhibitory potency and good oral bioavailability but high in vivo clearance. Further structure-activity relationship (SAR) studies of heterocyclic core modifications to replace the imidazole core as well as various linkers to the P1 group led to the discovery of compound 6f a potent FXIa inhibitor with selectivity against most of the relevant serine proteases. Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance) in multiple preclinical species. Compound 6f achieved robust antithrombotic efficacy in a rabbit efficacy model at doses which preserved hemostasis.
引用
收藏
页码:7226 / 7242
页数:17
相关论文
共 50 条
  • [1] Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor
    Chacko, Silvi A.
    Yang, Wu
    Wang, Yufeng
    Tian, Yuan
    Hong, Yang
    Wallace, Michael
    Wang, Bonnie
    Ewing, William R.
    Luettgen, Joseph M.
    Shu, Yue-Zhong
    Christopher, Lisa J.
    XENOBIOTICA, 2021, 51 (08) : 933 - 948
  • [2] Discovery of potent and orally bioavailable macrocyclic FXIa inhibitors
    Yang, Wu
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [3] Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
    Dilger, Andrew K.
    Pabbisetty, Kumar B.
    Corte, James R.
    De Lucca, Indawati
    Fang, Tianan
    Yang, Wu
    Pinto, Donald J. P.
    Wang, Yufeng
    Zhu, Yeheng
    Mathur, Arvind
    Li, Jianqing
    Hou, Xiaoping
    Smith, Daniel
    Sun, Dawn
    Zhang, Huiping
    Krishnananthan, Subramaniam
    Wu, Dauh-Rurng
    Myers, Joseph E., Jr.
    Sheriff, Steven
    Rossi, Karen A.
    Chacko, Silvi
    Zheng, Joanna J.
    Galella, Michael A.
    Ziemba, Theresa
    Dierks, Elizabeth A.
    Bozarth, Jeffrey M.
    Wu, Yiming
    Crain, Earl
    Wong, Pancras C.
    Luettgen, Joseph M.
    Wexler, Ruth R.
    Ewing, William R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (03) : 1770 - 1785
  • [4] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Pancras C. Wong
    Donald J. P. Pinto
    Donglu Zhang
    Journal of Thrombosis and Thrombolysis, 2011, 31 : 478 - 492
  • [5] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Wong, Pancras C.
    Pinto, Donald J. P.
    Zhang, Donglu
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (04) : 478 - 492
  • [6] Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase
    Mazur, Marzena
    Bartoszewicz, Agnieszka
    Dymek, Barbara
    Salamon, Magdalena
    Andryianau, Gleb
    Kowalski, Michal
    Olejniczak, Sylwia
    Matyszewski, Krzysztof
    Pluta, Elzbieta
    Borek, Bartlomiej
    Stefaniak, Filip
    Zagozdzon, Agnieszka
    Mazurkiewicz, Marcin
    Koralewski, Robert
    Czestkowski, Wojciech
    Piotrowicz, Michal
    Niedziejko, Piotr
    Gruza, Mariusz M.
    Dzwonek, Karolina
    Golebiowski, Adam
    Golab, Jakub
    Olczak, Jacek
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (03) : 310 - 314
  • [7] Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor
    Caenepeel, Sean
    Karen, Rex
    Belmontes, Brian
    Verlinsky, Alla
    Tan, Hong
    Yang, Yajing
    Chen, Xiaoyue
    Li, Kexue
    Allen, Jennifer
    Wahlstrom, Jan
    Canon, Jude
    Coxon, Angela
    Hughes, Paul
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
    Zhang, Hefeng
    Peng, Xia
    Dai, Yang
    Shao, Jingwei
    Ji, Yinchun
    Sun, Yiming
    Liu, Bo
    Cheng, Xu
    Ai, Jing
    Duan, Wenhu
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 3956 - 3975
  • [9] PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE NTCP INHIBITOR A7387
    Strangberg, Ellen
    Bonn, Britta
    Phuong Phan
    Uzelac, Ivana
    Starke, Ingemar
    Pal, Runa
    Gaur, Ashwani
    Kangarajan, Ramesh
    Singh, Shivendra
    Kulkarni, Santosh
    Dawson, Paul A.
    Lindstrom, Erik
    HEPATOLOGY, 2023, 78 : S582 - S582
  • [10] Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A
    Shen, Hong C.
    Szymonifka, Michael J.
    Kharbanda, Divya
    Denga, Qiaolin
    Carballo-Jane, Ester
    Wu, Kenneth K.
    Wu, Tsuei-Ju
    Cheng, Kang
    Ren, Ning
    Cai, Tian-Quan
    Taggart, Andrew K.
    Wang, Junying
    Tong, Xinchun
    Waters, M. Gerard
    Hammond, Milton L.
    Tata, James R.
    Colletti, Steven L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (24) : 6723 - 6728